Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation

World News: . []

NEW YORK July 17 2017 GLOBE NEWSWIRE -- Axsome Therapeutics Inc NASDAQAXSM a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system CNS disorders enrolled the first patient in the ADV...

More news and information about Axsome Therapeutics, Inc.

Published By:

Globe Newswire: 12:00 GMT Monday 17th July 2017

Published: .

Search for other references to "axsome" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers